5-[1-(2-Phenylpropan-2-yl)tetrazol-5-yl]pentanoic acid | 402958-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[1-(2-Phenylpropan-2-yl)tetrazol-5-yl]pentanoic acid
• CAS: 402958-20-7
• 化学式: C₁₅H₂₀N₄O₂
• 分子量: 288.349
• InChiKey: KNCBFZVXSSKVNM-UHFFFAOYSA-N

物化性质

• 沸点：
  533.1±39.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  80.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-[1-(2-Phenylpropan-2-yl)tetrazol-5-yl]pentanoic acid 在 sodium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 戴斯-马丁氧化剂 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 生成 [(3R,5S)-5-[[1-(cyclopropylamino)-1,2-dioxohexan-3-yl]carbamoyl]-1-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-[5-[1-(2-phenylpropan-2-yl)tetrazol-5-yl]pentanoylamino]butanoyl]amino]butanoyl]pyrrolidin-3-yl] 3,4-dihydro-1H-isoquinoline-2-carboxylate
  参考文献：
  名称：

  P4 cap modified tetrapeptidyl α-ketoamides as potent HCV NS3 protease inhibitors

  摘要：

  We describe herein the design, syntheses, and biological evaluation of new series of P4 tetrazole and adipic acid, ester, amide capped tetrapeptidyl alpha-ketoamide based HCV protease inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.078
• 作为产物：
  描述：

  5-溴戊酸甲酯 在 sodium hydroxide 、 sodium azide 、 三乙胺盐酸盐 、 三氯乙酸 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 5-[1-(2-Phenylpropan-2-yl)tetrazol-5-yl]pentanoic acid
  参考文献：
  名称：

  P4 cap modified tetrapeptidyl α-ketoamides as potent HCV NS3 protease inhibitors

  摘要：

  We describe herein the design, syntheses, and biological evaluation of new series of P4 tetrazole and adipic acid, ester, amide capped tetrapeptidyl alpha-ketoamide based HCV protease inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.078

文献信息

• Peptidomimetic protease inhibitors
  申请人：Babine Edward Robert

  公开号：US20050197299A1

  公开（公告）日：2005-09-08

  The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

  本发明涉及肽类似物化合物，可用作蛋白酶抑制剂，特别是丝氨酸蛋白酶抑制剂，更特别是丙型肝炎NS3蛋白酶抑制剂；其中间体；它们的制备包括新的立体选择性过程到中间体。本发明还涉及制药组合物和使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染相关的生理状况的患者的方法。还提供了包括一个或多个HCV丝氨酸蛋白酶抑制剂，一个或多个表现出抗HCV活性的干扰素和/或一个或多个具有抗HCV活性和药学上可接受的载体的药物组合物，以及使用该组合物治疗或预防患者的HCV感染的方法。本发明还涉及用于治疗或预防患者HCV感染的工具包或药品包装。
• Chiral intermediates for the preparation of peptidomimetic protease inhibitors
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1876173A1

  公开（公告）日：2008-01-09

  The present application relates to intermediate compounds according to formula (24,25,26 and 27) for the preparation of peptidomimetic compounds which are useful as protease inhibitors: wherein is optionally substituted fused arylcycloalkyl; R11 is -CO2R13; R12 is iminic glycinimide derivative adduct; and R13 is acid protecting group or optionally substituted aliphatic group. wherein: R15 is optionally substituted aliphatic group; and R16 is acid protecting group, optionally substituted aryl, or optionally substituted aliphatic group. wherein: p° is amide protecting group;

  本申请涉及中间化合物，其化学式为（24、25、26和27），用于制备肽类模拟化合物，这些化合物可用作蛋白酶抑制剂： 其中，X是可选取代的融合芳基环烷基；R11是-CO2R13；R12是亚胺基甘氨酰亚胺衍生物加合物；R13是酸保护基或可选取代的脂肪基。 其中，R15是可选取代的脂肪基；R16是酸保护基、可选取代的芳基或可选取代的脂肪基。 其中，p°是酰胺保护基。
• Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1878720B1

  公开（公告）日：2010-10-06
• PEPTIDOMIMETIC PROTEASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1320540B9

  公开（公告）日：2012-03-21
• Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection
  申请人：Vertex Pharmaceuticals Inc.

  公开号：EP2368877B1

  公开（公告）日：2014-05-07